Natera, Inc. (NTRA)

86.59 -0.69 (-0.79%) As of 09:37AM EDT. Market open.

Natera, Inc.

13011 McCallen Pass
Building A Suite 100
Austin, TX 78753
United States
650 980 9190
https://www.natera.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 3,282

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Matthew Rabinowitz Ph.D.	Co-Founder & Executive Chairman	441.58k	9.05M	1973
Mr. Steven Leonard Chapman	CEO & Director	1.15M	2.95M	1979
Mr. Michael B. Brophy M.B.A.	Chief Financial Officer	611.35k	N/A	1980
Mr. Daniel Rabinowitz L.L.M.	Secretary & Chief Legal Officer	566.03k	5.42M	1969
Mr. John Fesko	President & Chief Business Officer	N/A	N/A	N/A
Mr. Jonathan Sheena M.Eng.	Co-Founder & Director	293.91k	10.04M	1973
Ms. Olesya A. Anisimova CPA	Chief Accounting Officer	N/A	N/A	N/A
Mr. Rishi Kacker	Chief Technology Officer	N/A	N/A	N/A
Mr. Eric A. Evans	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jerry Diffley	Chief Compliance & Privacy Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Corporate Governance

Natera, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.